Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 8761 to 8775 of 8903 results

  1. NICE reaches important milestone in the UK's efforts to tackle antimicrobial resistance.

    Two new antimicrobial drugs are close to becoming the first to be made available as part of the UK’s innovative subscription-style payment model.

  2. Ovarian cancer patients to have NICE-approved drug combination option on Cancer Drugs Fund

    A potentially life-extending drug combination for some people with advanced, high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer will now be available on the Cancer Drugs Fund (CDF), following its approval by NICE in draft guidance published today.

  3. Over 700 people a year could benefit from a new lung cancer drug

    An innovative and potentially life-extending drug for treating people with a specific gene mutation of advanced non-small-cell lung cancer (NSCLC) has been recommended by NICE and will be available to patients from today (Thursday, 14 April).

  4. Patients with rare blood disorders to receive new treatment option, says NICE

    In final guidance published today (20 May 2021), NICE has recommended ravulizumab (Ultomiris, Alexion Pharmaceuticals) as a treatment for paroxysmal nocturnal haemoglobinuria (PNH). Draft guidance published 19 May 2021 also recommends the treatment for atypical haemolytic uraemic syndrome (aHUS).

  5. Make your voice heard on a NICE committee

    Home News Podcasts Make your voice heard on a NICE committee Podcasts 02 October 2024 Listen About this episode In this episode, we hear from

  6. More people could be offered genetic testing for genes linked to ovarian cancer

    A new draft NICE guideline for inherited ovarian cancer published today (15 September 2023), recommends more people are tested for genes linked to ovarian cancer.

  7. Adapted shoes recommended for people with severe osteoarthritis

    People with osteoarthritis who are eligible for knee surgery could be offered specially adapted shoes to help with their painful and stiff knees following a draft recommendation by NICE.

  8. Targeted treatment for rare form of aggressive lung cancer gets NICE approval

    Mobocertinib recommended as a treatment for a rare and aggressive form of lung cancer

  9. New life-extending treatment for rare forms of advanced gastroesophageal cancer

    Around 3,000 people could be eligible for a new life-extending combination therapy to treat rare forms of gastroesophageal cancer after NICE published final draft guidance today (24 November 2022).

  10. People who have had a stroke should be offered additional rehabilitation

    People who have had a stroke and who have continuing impairment or limitations on their activities should be offered additional rehabilitation to help them recover

  11. Keep the size of your waist to less than half of your height, NICE recommends

    People are being encouraged to keep their waist measurement to less than half their height to reduce the risk of potential health problems.

  12. Consultation on updated guideline to assess and prevent falls in older people

    We're seeking views from healthcare professionals and the public on draft recommendations covering assessments and interventions to reduce the risk of falls in older people.

  13. First targeted treatment to reduce the risk of ALK positive lung cancer returning after complete tumour removal recommended by NICE

    For the first time, we have recommended a targeted treatment option for ALK-positive non-small-cell lung cancer, to be given after surgery to reduce the risk of the disease coming back.

  14. Consultation on NHS England proposals for a phased launch of obesity injection

    Proposals for a phased launch of the obesity injection tirzepatide have been set out, as a consultation begins.

  15. NICE ready to work with company to address uncertainty in evidence for elacestrant for advanced breast cancer

    Today (1 October 2024) NICE is consulting on draft guidance that does not recommend elacestrant for treating a type of advanced breast cancer.